- Flavoxate hydrochloride
-
- $6.00 / 1KG
-
2024-04-12
- CAS:3717-88-2
- Min. Order: 25KG
- Purity: More than 99%
- Supply Ability: 2000KG/Month
- Flavoxate hydrochloride
-
- $110.00/ kilogram
-
2024-01-23
- CAS:3717-88-2
- Min. Order: 1kilogram
- Purity: 99%
- Supply Ability: 10 tons/per week
- metomidate
-
- $25.00 / 25kg
-
2023-12-25
- CAS:3717-88-2
- Min. Order: 25kg
- Purity: 99%
- Supply Ability: 20000000
|
| | Flavoxate hydrochloride Basic information |
| | Flavoxate hydrochloride Chemical Properties |
| Melting point | 232-234°C | | storage temp. | Inert atmosphere,Room Temperature | | solubility | H2O: ~6.6 mg/mL | | form | solid | | color | white | | InChI | InChI=1S/C24H25NO4.ClH/c1-17-21(26)19-11-8-12-20(23(19)29-22(17)18-9-4-2-5-10-18)24(27)28-16-15-25-13-6-3-7-14-25;/h2,4-5,8-12H,3,6-7,13-16H2,1H3;1H | | InChIKey | XOEVKNFZUQEERE-UHFFFAOYSA-N | | SMILES | C12OC(=C(C)C(=O)C=1C=CC=C2C(=O)OCCN1CCCCC1)C1C=CC=CC=1.Cl | | CAS DataBase Reference | 3717-88-2(CAS DataBase Reference) |
| Hazard Codes | Xn | | Risk Statements | 22-36/37/38 | | Safety Statements | 26 | | WGK Germany | 3 | | RTECS | DJ2450000 | | HS Code | 29349990 | | Toxicity | LD50 i.v. in rats: 27.4 mg/kg (Cazzulani) |
| | Flavoxate hydrochloride Usage And Synthesis |
| Chemical Properties | Flavoxate hydrochloride is Crystalline Solid | | Originator | Urispas,SKF,US,1971 | | Uses | Smooth muscle relaxant. Used as antispasmodic; in treatment of urinary incontinence. | | Uses | Antispasmodic;Phosphodiesterase inhibitor | | Definition | ChEBI: The hydrochloride salt of flavoxate. | | Manufacturing Process | A mixture of 13.3 grams of anhydrous aluminum chloride and 100 ml of
carbon disulfide is added to 19.4 grams of 2-propionyloxybenzoic acid
(prepared from the reaction of propionyl chloride and 2-hydroxybenzoic acid).
After an initial evolution of hydrogen chloride, the solvent is removed by
distillation and the mixture is heated at 150° to 160°C for 4 hours. The cooled
reaction mixture is treated with ice and hydrochloric acid and the product, 2-
hydroxy-3-carboxypropiophenone, is obtained from the oily residue by
distillation in vacuo.
A mixture of 1.9 grams of 2-hydroxy-3-carboxypropiophenone, 5.0 grams of
sodium benzoate and 20.0 grams of benzoic anhydride is heated at 180° to
190°C for 6 hours. A solution of 15.0 grams of potassium hydroxide in 50 ml
of ethanol and 20 ml of water is added and refluxed for 1 hour. The mixture is
evaporated and the residue after addition of water yields 3-methylflavone-8-
carboxylic acid.
To a suspension of 12.0 grams of 3-methylflavone-8-carboxylic acid in 200 ml
of anhydrous benzene is added 10.0 grams of thionyl chloride. The mixture is
refluxed for 2 hours during which the suspended solid goes into solution. The
solvent is completely removed by distillation, the residue extracted with
benzene and the extract evaporated to dryness. The product, 3-
methylflavone-8-carboxylic acid chloride, is recrystallized from ligroin to give
crystals melting at 155° to 156°C.
To 11.0 grams of 3-methylflavone-8-carboxylic acid chloride dissolved in 150
ml of anhydrous benzene is added at room temperature 4.8 grams of
piperidinoethanol and the mixture refluxed for 2 to 3 hours. The separated
solid is filtered, washed with benzene and dried. The product, piperidinoethyl
3-methylflavone-8-carboxylate hydrochloride is obtained as a colorless
crystalline solid, MP 232° to 234°C, (from US Patent 2,921,070). | | Brand name | Urispas (Ortho-McNeil). | | Therapeutic Function | Spasmolytic | | Side effects |
The following adverse reactions have been observed, but there are not enough data to support an estimate of their frequency.
Gastrointestinal: Nausea, vomiting, dry mouth.
CNS: Vertigo, headache, mental confusion, especially in the elderly, drowsiness, nervousness.
Hematologic: Leukopenia (one case which was reversible upon discontinuation of the drug).
Cardiovascular: Tachycardia and palpitation.
Allergic: Urticaria and other dermatoses, eosinophilia and hyperpyrexia.
Ophthalmic: Increased ocular tension, blurred vision, disturbance in eye accommodation.
Renal: Dysuria.
| | Veterinary Drugs and Treatments | Flovoxate may be considered for treating dogs with detrusor hyperspasticity
(hyperactive bladder, urge incontinence). | | Pharmacology | Flavoxate hydrochloride counteracts smooth muscle spasm of the urinary tract and exerts its effect directly on the muscle. In a single study of 11 normal male subjects, the time to onset of action was 55 minutes. The peak effect was observed at 112 minutes. 57% of the flavoxate hydrochloride was excreted in the urine within 24 hours. |
| | Flavoxate hydrochloride Preparation Products And Raw materials |
|